Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Apr 3;82(9):1577–1584. doi: 10.1054/bjoc.1999.1180

Urinary androgens and breast cancer risk: results from a long-term prospective study based in Guernsey

D Y Wang 1, D S Allen 2, B L De Stavola 3, I S Fentiman 3, J Brussen 3, R D Bulbrook 2, B S Thomas 2, J L Hayward 2, M J Reed 1
PMCID: PMC2363403  PMID: 10789728

Abstract

Between 1961 and 1967 a cohort of over 5000 women volunteered for a prospective study to determine the relationship between the urinary androgen metabolites, androsterone (A) and aetiocholanolone (E), and risk of breast cancer. During the first 10 years of the study the concentration of urinary A and E was determined in 1887 of the urine specimens. In 1971 we reported that subnormal amounts of urinary A and E were associated with a significantly increased risk of breast cancer. The cohort has been followed regularly during the 37 years since inception of the study and, by May 1998, 248 women had been diagnosed with breast cancer. Urinary androgen metabolites had been measured in 116 of these cases. Analysis of these data confirmed that women diagnosed in the first decade of the study were more likely to have low levels of urinary androgen metabolites. In the following decades, however, those who developed breast cancer were more likely to have manifested an increased A and E excretion. The reversal in the relationship between androgen metabolite excretion and risk suggests that age, or probably more importantly, menopausal status at diagnosis is an important modifying factor. Dichotomizing at age 50 it was found that in the younger age group (predominantly premenopausal) the rate ratios in the lowest tertile of A or E excretion were two- to threefold greater than for those in the highest tertile (χ21= 3.57;P = 0.06: χ21= 4.70;P = 0.03 for A and E respectively). In contrast, in the older age group comprising predominantly post-menopausal women, the rate ratios associated with the lowest tertile of A or E were half that of those in the highest tertile (χ21= 4.10;P = 0.04; χ21= 8.72;P = 0.003 for A and E respectively). This suggests that there may be different endocrine promotional factors for pre-and post-menopausal breast cancer. Hormonal risk factors may vary during the lifetime of an individual woman and this may have profound consequences for prevention strategies. © 2000 Cancer Research Campaign

Keywords: breast cancer risk, adrenal androgens, androsterone, aetiocholanolone, menopause

Full Text

The Full Text of this article is available as a PDF (119.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adami H. O., Johansson E. D., Vegelius J., Victor A. Serum concentrations of estrone, androstenedione, testosterone and sex-hormone-binding globulin in postmenopausal women with breast cancer and in age-matched controls. Ups J Med Sci. 1979;84(3):259–274. doi: 10.3109/03009737909179163. [DOI] [PubMed] [Google Scholar]
  2. Adams J. B. Adrenal androgens and human breast cancer: a new appraisal. Breast Cancer Res Treat. 1998 Sep;51(2):183–188. doi: 10.1023/a:1006050720900. [DOI] [PubMed] [Google Scholar]
  3. Bonney R. C., Scanlon M. J., Reed M. J., Jones D. L., Beranek P. A., James V. H. Adrenal androgen concentrations in breast tumours and in normal breast tissue. The relationship to oestradiol metabolism. J Steroid Biochem. 1984 Jan;20(1):501–504. doi: 10.1016/0022-4731(84)90261-9. [DOI] [PubMed] [Google Scholar]
  4. Bulbrook R. D., Hayward J. L. Abnormal urinary steroid excretion and subsequent breast cancer. A prospective study in the Island of Guernsey. Lancet. 1967 Mar 11;1(7489):519–522. doi: 10.1016/s0140-6736(67)92107-1. [DOI] [PubMed] [Google Scholar]
  5. Bulbrook R. D., Hayward J. L., Spicer C. C. Relation between urinary androgen and corticoid excretion and subsequent breast cancer. Lancet. 1971 Aug 21;2(7721):395–398. doi: 10.1016/s0140-6736(71)90113-9. [DOI] [PubMed] [Google Scholar]
  6. DE WAARD F., BAANDERS-VANHALEWIJN E. A., HUIZINGA J. THE BIMODAL AGE DISTRIBUTION OF PATIENTS WITH MAMMARY CARCINOMA; EVIDENCE FOR THE EXISTENCE OF 2 TYPES OF HUMAN BREAST CANCER. Cancer. 1964 Feb;17:141–151. doi: 10.1002/1097-0142(196402)17:2<141::aid-cncr2820170202>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  7. Dorgan J. F., Longcope C., Stephenson H. E., Jr, Falk R. T., Miller R., Franz C., Kahle L., Campbell W. S., Tangrea J. A., Schatzkin A. Relation of prediagnostic serum estrogen and androgen levels to breast cancer risk. Cancer Epidemiol Biomarkers Prev. 1996 Jul;5(7):533–539. [PubMed] [Google Scholar]
  8. Grattarola R., Secreto G., Recchione C., Castellini W. Androgens in breast cancer. II. Endometrial adenocarcinoma and breast cancer in married postmenopausal women. Am J Obstet Gynecol. 1974 Jan 15;118(2):173–178. [PubMed] [Google Scholar]
  9. HUGGINS C., JENSEN E. V., CLEVELAND A. S. Chemical structure of steroids in relation to promotion of growth of the vagina and uterus of the hypophysectomized rat. J Exp Med. 1954 Sep 1;100(3):225–240. doi: 10.1084/jem.100.3.225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hayward J. L., Greenwood F. C., Glober G., Stemmerman G., Bulbrook R. D., Wang D. Y., Kumaokas S. Endocrine status in normal British, Japanese and Hawaiian-Japanese women. Eur J Cancer. 1978 Nov;14(11):1221–1228. doi: 10.1016/0014-2964(78)90228-1. [DOI] [PubMed] [Google Scholar]
  11. Hill P., Garbaczewski L., Kasumi F. Plasma testosterone and breast cancer. Eur J Cancer Clin Oncol. 1985 Oct;21(10):1265–1266. doi: 10.1016/0277-5379(85)90025-2. [DOI] [PubMed] [Google Scholar]
  12. Hsieh C. C., Trichopoulos D., Katsouyanni K., Yuasa S. Age at menarche, age at menopause, height and obesity as risk factors for breast cancer: associations and interactions in an international case-control study. Int J Cancer. 1990 Nov 15;46(5):796–800. doi: 10.1002/ijc.2910460508. [DOI] [PubMed] [Google Scholar]
  13. KELLIE A. E., WADE A. P. The analysis of urinary 17-oxo steroids by gradient elution. Biochem J. 1957 Jun;66(2):196–206. doi: 10.1042/bj0660196. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Key T. J., Pike M. C. The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol. 1988 Jan;24(1):29–43. doi: 10.1016/0277-5379(88)90173-3. [DOI] [PubMed] [Google Scholar]
  15. Key T. J., Wang D. Y., Brown J. B., Hermon C., Allen D. S., Moore J. W., Bulbrook R. D., Fentiman I. S., Pike M. C. A prospective study of urinary oestrogen excretion and breast cancer risk. Br J Cancer. 1996 Jun;73(12):1615–1619. doi: 10.1038/bjc.1996.304. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Lynch H. T., Lynch J. F. Breast cancer genetics in an oncology clinic: 328 consecutive patients. Cancer Genet Cytogenet. 1986 Aug;22(4):369–371. doi: 10.1016/0165-4608(86)90032-4. [DOI] [PubMed] [Google Scholar]
  17. Manton K. G., Stallard E. A two-disease model of female breast cancer: mortality in 1969 among white females in the United States. J Natl Cancer Inst. 1980 Jan;64(1):9–16. [PubMed] [Google Scholar]
  18. McFadyen I. J., Forrest A. P., Prescott R. J., Golder M. P., Groom G. V., Fahmy D. R., Griffiths K. Circulating hormone concentrations in women with breast cancer. Lancet. 1976 May 22;1(7969):1100–1102. doi: 10.1016/s0140-6736(76)90064-7. [DOI] [PubMed] [Google Scholar]
  19. Powles T., Eeles R., Ashley S., Easton D., Chang J., Dowsett M., Tidy A., Viggers J., Davey J. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet. 1998 Jul 11;352(9122):98–101. doi: 10.1016/S0140-6736(98)85012-5. [DOI] [PubMed] [Google Scholar]
  20. Reed M. J. The discriminant-function test: a marker of Th1/Th2 cell cytokine secretion and breast tumour oestrogen synthesis. Mol Med Today. 1995 May;1(2):98–103. doi: 10.1016/s1357-4310(95)92435-3. [DOI] [PubMed] [Google Scholar]
  21. Salber E. J., Trichopulos D., MacMahon B. Lactation and reproductive histories of breast cancer patients in Boston, 1965-66. J Natl Cancer Inst. 1969 Nov;43(5):1013–1024. [PubMed] [Google Scholar]
  22. Secreto G., Recchione C., Cavalleri A., Miraglia M., Dati V. Circulating levels of testosterone, 17 beta-oestradiol, luteinising hormone and prolactin in postmenopausal breast cancer patients. Br J Cancer. 1983 Feb;47(2):269–275. doi: 10.1038/bjc.1983.35. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Secreto G., Toniolo P., Berrino F., Recchione C., Cavalleri A., Pisani P., Totis A., Fariselli G., Di Pietro S. Serum and urinary androgens and risk of breast cancer in postmenopausal women. Cancer Res. 1991 May 15;51(10):2572–2576. [PubMed] [Google Scholar]
  24. Secreto G., Zumoff B. Abnormal production of androgens in women with breast cancer. Anticancer Res. 1994 Sep-Oct;14(5B):2113–2117. [PubMed] [Google Scholar]
  25. Seymour-Munn K., Adams J. Estrogenic effects of 5-androstene-3 beta, 17 beta-diol at physiological concentrations and its possible implication in the etiology of breast cancer. Endocrinology. 1983 Feb;112(2):486–491. doi: 10.1210/endo-112-2-486. [DOI] [PubMed] [Google Scholar]
  26. Thomas B. S., Walton D. R. Chloromethyldimethylsilyl ethers in the routine assay of urinary 11-deoxy-17-oxosteroids by gas-liquid chromatography. J Endocrinol. 1968 Jun;41(2):203–211. doi: 10.1677/joe.0.0410203. [DOI] [PubMed] [Google Scholar]
  27. Thomas H. V., Key T. J., Allen D. S., Moore J. W., Dowsett M., Fentiman I. S., Wang D. Y. A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey. Br J Cancer. 1997;76(3):401–405. doi: 10.1038/bjc.1997.398. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Thomas H. V., Key T. J., Allen D. S., Moore J. W., Dowsett M., Fentiman I. S., Wang D. Y. A prospective study of endogenous serum hormone concentrations and breast cancer risk in premenopausal women on the island of Guernsey. Br J Cancer. 1997;75(7):1075–1079. doi: 10.1038/bjc.1997.183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Thomas H. V., Reeves G. K., Key T. J. Endogenous estrogen and postmenopausal breast cancer: a quantitative review. Cancer Causes Control. 1997 Nov;8(6):922–928. doi: 10.1023/a:1018476631561. [DOI] [PubMed] [Google Scholar]
  30. Toniolo P. G., Levitz M., Zeleniuch-Jacquotte A., Banerjee S., Koenig K. L., Shore R. E., Strax P., Pasternack B. S. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst. 1995 Feb 1;87(3):190–197. doi: 10.1093/jnci/87.3.190. [DOI] [PubMed] [Google Scholar]
  31. Veronesi U., Maisonneuve P., Costa A., Sacchini V., Maltoni C., Robertson C., Rotmensz N., Boyle P. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet. 1998 Jul 11;352(9122):93–97. doi: 10.1016/s0140-6736(98)85011-3. [DOI] [PubMed] [Google Scholar]
  32. Wang D. Y., De Stavola B. L., Bulbrook R. D., Allen D. S., Kwa H. G., Fentiman I. S., Hayward J. L., Millis R. R. Relationship of blood prolactin levels and the risk of subsequent breast cancer. Int J Epidemiol. 1992 Apr;21(2):214–221. doi: 10.1093/ije/21.2.214. [DOI] [PubMed] [Google Scholar]
  33. Wang D. Y., DeStavola B. L., Allen D. S., Fentiman I. S., Bulbrook R. D., Hayward J. L., Reed M. J. Breast cancer risk is positively associated with height. Breast Cancer Res Treat. 1997 Apr;43(2):123–128. doi: 10.1023/a:1005796511513. [DOI] [PubMed] [Google Scholar]
  34. Wang D. Y., Moore J. W., Thomas B. S., Bulbrook R. D., Hoare S. A., Tong D., Hayward J. L. Plasma and urinary androgens in women with varying degrees of risk of breast cancer. Eur J Cancer. 1979 Oct;15(10):1269–1274. doi: 10.1016/0014-2964(79)90253-6. [DOI] [PubMed] [Google Scholar]
  35. Zeleniuch-Jacquotte A., Bruning P. F., Bonfrer J. M., Koenig K. L., Shore R. E., Kim M. Y., Pasternack B. S., Toniolo P. Relation of serum levels of testosterone and dehydroepiandrosterone sulfate to risk of breast cancer in postmenopausal women. Am J Epidemiol. 1997 Jun 1;145(11):1030–1038. doi: 10.1093/oxfordjournals.aje.a009059. [DOI] [PubMed] [Google Scholar]
  36. Zhang Y., Kiel D. P., Kreger B. E., Cupples L. A., Ellison R. C., Dorgan J. F., Schatzkin A., Levy D., Felson D. T. Bone mass and the risk of breast cancer among postmenopausal women. N Engl J Med. 1997 Feb 27;336(9):611–617. doi: 10.1056/NEJM199702273360903. [DOI] [PubMed] [Google Scholar]
  37. de WAARD, de LAIVE J., BAANDERS-VANHALEWIJN E. A. On the bimodal age distribution of mammary carcinoma. Br J Cancer. 1960 Sep;14:437–448. doi: 10.1038/bjc.1960.47. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. van Doorn L. G., Poortman J., Thijssen J. H., Schwarz F. Actions and interactions of delta 5-androstene-3 beta, 17 beta-diol and 17 beta-estradiol in the immature rat uterus. Endocrinology. 1981 Apr;108(4):1587–1593. doi: 10.1210/endo-108-4-1587. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES